The US Food and Drug Administration (FDA) has approved the first-ever generic version of Saxenda (Liraglutide injection), a GLP-1 therapy indicated for weight loss by Teva Pharmaceuticals.

The drug is approved for adults with obesity or overweight who have weight-related medical conditions, as well as for paediatric patients aged 12 to 17 years weighing more than 60 kg with obesity. It is intended to be used alongside a reduced-calorie diet and increased physical activity to help patients lose weight and maintain long-term weight reduction.

“With this approval, and by launching a generic for Saxenda (Liraglutide injection), we will provide patients in the US the first-ever generic GLP-1 product specifically indicated for weight loss. This is the fifth first-to-market entry of a Teva generic this year, and is an important addition to Teva's diverse complex generics portfolio, demonstrating once again our proven ability to sustain a generics powerhouse, said Ernie Richardsen, SVP, Head–US, Commercial Generics, Teva Pharmaceuticals.

According to IQVIA, Saxenda recorded annual sales of USD 165 million in the US as of June 2025. Teva said the launch underscores its “Pivot to Growth” strategy, with a focus on expanding its complex generics pipeline.

The Liraglutide injection, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, adds to the company’s leadership in providing lower-cost alternatives to complex therapies in high-demand treatment categories, including those addressing the growing US obesity market.